Pliant Therapeutics (PLRX) AI Stock Analysis

• Market Cap: $90.24M
• Dividend Yield: N/A
• Average Volume (3M): 958.24K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.24
• Revenue Growth: -100.00%
• EPS Growth: -26.44%
• Country: US
• Employees: 171
• Sector: Healthcare
• Sector Strength: 48
• Industry: Biotechnology
• EPS (TTM): -0.92
• Shares Outstanding: 61,386,276
• 10 Day Avg. Volume: 684,749
• 30 Day Avg. Volume: 958,239
• PEG Ratio: <0.01
• Price to Book (P/B): 0.29
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.56
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $4.79
• Price Target Upside: 225.85% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 12

Pliant Therapeutics is currently facing substantial financial difficulties, with zero revenue in 2024 and ongoing net losses. These challenges are reflected in the low financial performance score. Technical analysis shows bearish trends but hints at a potential short-term rebound. Valuation remains poor due to a negative P/E ratio and lack of dividends. Additionally, a significant workforce reduction indicates further strategic challenges. Overall, these factors contribute to a low stock score, indicating high risk and limited appeal for potential investors.

Positive Factors

Clinical Trials

PLN-101095 showed a partial response rate of 50% at the highest dose cohort.

Oncology Progress

The first-in-human Phase 1 study is now enrolling patients to the fourth of five cohorts, demonstrating PLN-101095's anti-tumor activity when combined with pembrolizumab in patients with immune checkpoint inhibitor-refractory advanced or metastatic solid tumors.

Negative Factors

Clinical Trial Setback

Pliant announced the discontinuation of the Phase IIb/III BEACON-IPF study for bexotegrast due to a higher rate of IPF-related adverse events observed in the bexo-treated groups of the study, compared to the placebo group.

Workforce Reduction

The company has announced a workforce reduction of ~45% to minimize costs and conserve cash.

Pliant Therapeutics Business Overview & Revenue Model

Company Description

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials. The company also develops PLN-1474, a small-molecule selective inhibitor of avß1, which completed Phase 1 clinical trial for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition, it is developing two additional preclinical integrin-based programs, which include an oncology program, as well as a program for an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor for treatment of muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.

How the Company Makes Money

Pliant Therapeutics makes money primarily through the development and potential commercialization of its drug candidates. The company generates revenue through strategic partnerships and collaborations with larger pharmaceutical companies. These partnerships may involve upfront payments, milestone payments based on the achievement of specific development goals, and royalties on future product sales. As a clinical-stage company, Pliant's revenue is also influenced by research grants or subsidies, but the majority of its future earnings potential lies in the successful approval and market introduction of its drug candidates.

Pliant Therapeutics Financial Statement Overview

Summary

Pliant Therapeutics is facing significant financial challenges with declining revenues and persistent losses. The balance sheet remains relatively stable with low leverage, but cash flows are under pressure, necessitating external funding to support operations. The company needs to improve revenue generation and cost management to achieve financial stability.

Income Statement

Pliant Therapeutics has shown a declining revenue trend from 2019 to 2024 with revenue dropping to zero in 2024. The company is experiencing persistent net losses, evident from the negative net profit margins, indicating challenges in achieving profitability. EBIT and EBITDA margins are also negative, reflecting high operating expenses relative to revenue.

Balance Sheet

The company's balance sheet shows a stable equity base despite consistent losses. The debt-to-equity ratio remains low due to minimal debt, signaling low leverage which reduces financial risk. However, the company's stockholders' equity has decreased over time, indicating financial pressure.

Cash Flow

Pliant Therapeutics has negative operating and free cash flows, indicating cash outflows from operations. The free cash flow has worsened over time, showing increasing capital strain. The cash flow from financing activities has been positive, suggesting reliance on external funding.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
0.00	1.58M	9.69M	7.57M	41.82M
	Gross Profit
0.00	1.58M	6.00M	4.37M	41.82M
	EBIT
-228.37M	-184.15M	-127.20M	-19.99M	-41.65M
	EBITDA
-228.37M	-158.23M	-118.85M	-95.73M	-40.34M
	Net Income Common Stockholders
-210.30M	-161.34M	-121.50M	-17.91M	-39.74M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
355.72M	494.25M	331.19M	200.60M	276.89M
	Total Assets
396.95M	512.15M	350.61M	221.22M	295.53M
	Total Debt
29.98M	11.37M	15.81M	7.19M	283.00K
	Net Debt
-41.21M	-51.86M	-17.87M	-44.47M	-50.60M
	Total Liabilities
92.87M	38.58M	37.27M	22.16M	12.46M
	Stockholders Equity
304.08M	473.58M	313.34M	199.06M	283.06M
Cash Flow		Free Cash Flow
-159.35M	-117.28M	-96.39M	-77.40M	-38.80M
	Operating Cash Flow
-155.50M	-116.36M	-94.63M	-75.44M	-37.27M
	Investing Cash Flow
140.34M	-127.01M	-150.20M	73.70M	-210.87M
	Financing Cash Flow
23.12M	274.40M	226.85M	2.53M	213.21M

Pliant Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.47
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PLRX, the sentiment is Negative. The current price of 1.47 is below the 20-day moving average (MA) of 1.50, below the 50-day MA of 1.48, and below the 200-day MA of 9.33, indicating a bearish trend. The MACD of -0.09 indicates Negative momentum. The RSI at 39.28 is Neutral, neither overbought nor oversold. The STOCH value of 19.09 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PLRX.

Pliant Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$5.22B	3.55	-44.39%	2.82%	15.40%	-0.09%
MGNX	50 Neutral	$100.31M	―	-49.85%	―	155.26%	-640.36%
VERU	45 Neutral	$76.37M	―	-88.03%	―	-21.28%	36.26%
SRZN	43 Neutral	$68.50M	―	-456.32%	―	―	0.13%
CLYM	41 Neutral	$83.79M	―	-46.26%	―	―	-61.95%
PLRX	37 Underperform	$90.24M	―	-63.22%	―	-100.00%	-26.44%
ATOS	36 Underperform	$108.10M	―	-34.87%	―	―	15.09%

Pliant Therapeutics Corporate Events

Pliant Therapeutics Announces Major Workforce Reduction

On May 1, 2025, Pliant Therapeutics announced a significant workforce reduction, impacting approximately 45% of its employees, expected to be completed by the end of the second quarter of 2025. This move includes the termination of Chief Legal and Compliance Officer Mike Ouimette’s employment and is anticipated to result in $3.6 million in severance and related benefits, reflecting a strategic shift that may affect the company’s operational dynamics and stakeholder interests.

Spark’s Take on PLRX Stock

According to Spark, TipRanks’ AI Analyst, PLRX is a Underperform.

Pliant Therapeutics faces major financial difficulties with zero revenue in 2024 and persistent net losses, impacting its overall stability. Technical indicators suggest a bearish trend, but the stock is nearing oversold levels, which might offer potential for a short-term rebound. Despite a stable balance sheet, the negative P/E ratio and lack of dividends make the stock less appealing from a valuation standpoint.

To see Spark’s full report on PLRX stock, click here.

Pliant Therapeutics Adopts Stockholder Rights Agreement

On March 12, 2025, Pliant Therapeutics’ board of directors adopted a stockholder rights agreement to protect against hostile takeovers by issuing a dividend of one preferred share purchase right for each outstanding share of common stock. This move aims to prevent any entity from gaining control of the company without paying a control premium, ensuring that the board has the opportunity to act in the best interests of all stockholders. The rights become exercisable if a person or group acquires 10% or more of the company’s common stock without board approval, allowing existing stockholders to purchase additional shares at a discount, thus diluting the acquiring party’s stake.